Small Cap📈 NASDAQ: XERS
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Published 27 November 2025US Equity Report
Xeris Biopharma Holdings, Inc.
NASDAQ: XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies. Headquartered in Chicago, IL, and founded in 2005 by Steven Prestrelski, the company offers three main products: Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, approved in the U.S. for treating cert
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
US Equity Report
A$5000.00
Already a subscriber?
Sign in to read this report.
Required subscription
US Equity Report
Expand beyond the ASX with expert research on carefully selected U.S. stocks, covering market leaders, emerging opportunities, and global investment trends.
- ✓ U.S. Stock Research & Analysis
- ✓ Delivered every Friday
- ✓ Company & Industry Analysis
- ✓ Full Historical Report Access
A$5000.00/ 12 months
Risk:Medium
Subscribe Now →
